The cystic fibrosis transmembrane conductance regulator (CFTR) in addition to its well defined Cl ؊ channel properties regulates other ion channels. CFTR inhibits epithelial Na ؉ channel (ENaC) currents in many epithelial and non-epithelial cells, whereas the presence of ENaC increases CFTR functional expression. This interregulation is reproduced in Xenopus oocytes where both the open probability and surface expression of wild type CFTR Cl ؊ channels are increased when CFTR is coexpressed with ␣␤␥-mouse ENaC (mENaC) and conversely when the activity of mENaC is inhibited after wild type CFTR activation. Using the Xenopus oocyte expression system, different functional regulatory interactions were observed between G551D-CFTR and ␣␤␥-mENaC. The co-expression of G551D-CFTR and ␣␤␥-mENaC resulted in a 5-fold increase in G551D-CFTR Cl ؊ current compared with oocytes expressing G551D-CFTR alone. Oocytes co-injected with both G551D-CFTR and ENaC expressed an amiloride-sensitive whole cell current that was similar to that observed before and after G551D-CFTR activation with forskolin/isobutylmethylxanthine. Treatment with genistein both enhanced the functional expression of G551D-CFTR and improved regulatory interactions between G551D-CFTR and ENaC. These data suggest that genistein may be useful in patients with cystic fibrosis and the G551D-CFTR mutation.
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Cystic fibrosis (CF)
1 results from mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) (1) . In addition to functioning as a cAMP-activated ATP-dependent Cl Ϫ channel, CFTR influences the transepithelial transport of other solutes including Na ϩ via the epithelial sodium channel (ENaC), Cl Ϫ via an outwardly rectifying Cl Ϫ channel, K ϩ via Kir1.1, HCO3 Ϫ , and ATP (2) (3) (4) (5) . Functional interactions between CFTR and ENaC have been observed in epithelial as well as non-epithelial cells (6 -12) . The activation of CFTR is generally associated with an inhibition of ENaC (7, 8, 10, 11, 13, 14) , although activation of CFTR leads to activation of ENaC in the sweat duct (12) , suggesting that the regulatory interactions between these two transporters are complex. The co-expression of CFTR and rodent ENaC in Xenopus oocytes results in regulatory interactions that mimic the airway, i.e. a decrease in ENaC-mediated Na ϩ transport in the presence of CFTR (9 -11, 14) . Furthermore, CFTR-mediated Cl Ϫ conductance is increased in presence of ENaC (4, (7) (8) (9) (10) (11) 14) . In contrast, the ⌬F508-CFTR mutation, the most prevalent mutation found in North American Caucasian patients with CF, does not inhibit the functional expression of rat (15) or mouse ENaC (mENaC) (11) , and these ENaCs do not enhance the functional expression of ⌬F508-CFTR in Xenopus oocytes (11) . The isoflavone genistein, which activates the Cl Ϫ conductance of both wild type and mutant CFTRs (16 -19) , can restore these interactions (11) .
The G551D mutation in CFTR results in a channel that is appropriately localized to the apical membrane but does not normally conduct Cl Ϫ in response to cAMP stimulation (20) . Genistein can improve G551D-CFTRs cAMP-dependent chloride transport (19) . Others have shown that G551D-CFTR does not inhibit sodium transport by ENaC in Xenopus oocytes (6) . We hypothesized that genistein would restore the functional interactions between G551D-CFTR and mENaC and examined this interaction in the Xenopus oocyte expression system. ENaC was able to enhance the functional expression of G551D-CFTR in the absence of genistein, in contrast to our previous results examining interactions between ⌬F508-CFTR and ENaC (11) . In agreement with previous data, we observed that G551D-CFTR did not inhibit the functional expression of ENaC after activation with IBMX/forskolin (6). As we observed with ⌬F508-CFTR, genistein restored functional interactions between G551D-CFTR and ENaC.
EXPERIMENTAL PROCEDURES
Materials-Forskolin, IBMX, and genistein were purchased from Sigma. All other reagents were purchased from Fisher Chemical Company.
Expression of Human G551D-CFTR and Mouse ENaC in Xenopus
Oocytes-Human G551D-CFTR and mouse ENaC were expressed in Xenopus oocytes as described previously (10, 11) . Human G551D-CFTR and mouse ␣-, ␤-, and ␥-ENaC cRNAs were prepared using a cRNA synthesis kit (mMESSAGE mMachine, Ambion Inc, Austin, TX) according to the manufacturer's protocol. cRNA concentrations were determined spectroscopically. Oocytes obtained from adult female Xenopus laevis (NASCO, Fort Atkinson, WI) were enzymatically defolliculated * This work was supported in part by National Institutes of Health Grants DK56305 (to T. R. K.) and DK58046 (to R. C. R.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
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* 4 , 15 mM Hepes, pH 7.6, supplemented with 10 g/ml sodium penicillin, 10 g/ml streptomycin sulfate, and 100 g/ml gentamicin sulfate). Each batch of oocytes obtained from an individual frog was injected (50 nl/oocyte) using a Nanoject II microinjector (Drummond Scientific, Broomall, PA) with ␣, ␤, and ␥ subunits of mENaC (0.33 ng/subunit), G551D-CFTR (10 ng), or a combination of mENaC and G551D-CFTR cRNAs dissolved in RNase-free water.
Electrophysiological Analyses-Whole cell current measurements were performed 24 -48 h after injection using the two-electrode voltage clamp method as described previously (10, 11) . Oocytes were placed in a 1-ml chamber containing modified ND96 (96 mM NaCl, 1 mM KCl, 0.2 mM CaCl 2 , 5.8 mM MgCl 2 , and 10 mM Hepes, pH 7.4) and impaled with micropipettes of 0.5-5-megohm resistance filled with 3 M KCl. The whole cell currents were measured by voltage-clamping the oocytes in 20-mV steps between Ϫ140 and ϩ60 mV adjusted for base-line transmembrane potential. Whole cell currents (I) were digitized at 200 Hz during the voltage steps, recorded directly onto a hard disk, and analyzed using pClamp 8 software (Axon Instruments, Foster City, CA). Ion replacement studies were performed in an identical manner with the exception that equimolar N-methyl-D-glucamine (NMDG ϩ ) replaced Na ϩ in the ND96 solution. To reduce error due to series resistance, the voltage clamp (Axon Geneclamp 500B) was configured to clamp the bath potential to 0 mV. In this configuration, we independently monitored the oocyte membrane potential during our clamp protocol and routinely observed membrane potentials that were Ͻ5% depolarized from our target holding potentials.
The difference in whole cell currents measured in the absence and presence of 10 M amiloride was used to define the amiloride-sensitive Na ϩ current that was carried by ENaC. G551D-CFTR was activated by perfusion of the oocyte with buffer containing 10 M forskolin and 100 M IBMX for 25 min (10, 11) . In some experiments, this first step was followed by incubation with 10 M forskolin, 100 M IBMX, and 50 M genistein for 20 min. In all experiments, G551D-CFTR Cl Ϫ current was defined as the difference between amiloride-insensitive current measured before and after perfusion with forskolin/IBMX (or before and after perfusion with forskolin/IBMX/genistein). Whole cell currents were recorded at a clamp potential of Ϫ100 mV for comparisons. All measurements were performed at room temperature.
Single Channel Recordings-Bath and pipette solutions were identical and contained 110 mM N-methyl-D-glucamine, 1.8 mM CaCl 2 , 2.5 mM KCl, and 10 mM Hepes, pH 7. 4, 1.5 GHz PC (Gateway, Inc.). Single channel recording data were acquired using pClamp 8.1 (Axon) at 4 kHz, filtered at 1000 Hz by a 4-pole low pass Bessel Filter built in the amplifier, and stored on the hard disk. Single channel currents were further filtered at 500 Hz with a Gaussian filter for display purposes. Recordings were performed at Ϫ80 mV. pCLAMP version 6.0 and Clampfit 8.1 (Axon) and SigmaPlot version 2001 (Jandel Scientific, Corte Madera, CA) software were used for data analysis and plotting, respectively. The open probability (P o ) was calculated as P o ϭ I/(n ϫ i) where I is the mean current, n is the number of channels in the patch, and i is the single channel current.
Statistical Analyses-Statistical comparisons were performed using the Student's t test. A pairwise t test was used for pretreatment and posttreatment in experiments using an individual oocyte. A two-tailed t test was used when comparing currents obtained from oocytes injected with a cRNA for a single transporter (i.e. ENaC or G551D-CFTR versus oocytes co-injected with a cRNAs for both ENaC and G551D-CFTR). p values Ͻ 0.05 were accepted to indicate statistical significance.
RESULTS

Functional Expression of G551D-CFTR in Xenopus
Oocytes-We used the Xenopus oocyte expression system and twoelectrode voltage clamp technique to examine the functional expression of G551D-CFTR. We measured whole cell currents at varying clamping potentials in oocytes expressing G551D-CFTR ( Fig. 1) and generated I/V curves from data obtained prior to and after 20 min of incubation with 10 M forskolin and 100 M IBMX to activate endogenous protein kinase A (Fig.  1A) . Whole cell currents measured at a holding potential of Ϫ100 mV (adjusted for resting membrane potential) increased two-fold from Ϫ0.1 Ϯ 0.0 to Ϫ0.2 Ϯ 0.1 A (mean Ϯ S.E., n ϭ 22, p ϭ 0.006) in response to forskolin/IBMX. These data are consistent with previous observations that forskolin/IBMXstimulated chloride current in G551D-CFTR-expressing oocytes is very low (14) . As the isoflavone genistein is able to stimulate G551D-CFTR chloride conductance (19) , whole cell currents in G551D-CFTR-expressing oocytes were assessed before and after additional stimulation with 50 M genistein (in addition to IBMX and forskolin). Fig. 1B demonstrates the I/V relationship prior to and after activation of G551D-CFTR by 25 min of incubation with 10 M forskolin and 100 M IBMX followed by 15 min of incubation with 10 M forskolin, 100 M IBMX, and 50 M genistein. Whole cell currents measured at a clamp potential of Ϫ100 mV increased 4.4-fold from Ϫ0.09 Ϯ 0.0 to Ϫ0.4 Ϯ 0.1 A (n ϭ 21, p Ͻ 0.001) after the addition of IBMX, forskolin, and genistein. These data are consistent with IBMX/forskolin-stimulated G551D-CFTR-mediated chloride current being enhanced by genistein in Xenopus oocytes.
Given the small magnitude of the whole oocyte current in these experiments, it is possible that the regulation of endogenous channels may contribute to these observations. However, we do not feel that modulation of endogenous currents confound our data. Forskolin, IBMX, and genistein did not alter whole cell currents in oocytes that had not been injected with G551D-CFTR (n ϭ 3). We also assessed the I/V relationship of G551D-CFTR-injected oocytes in the presence of inhibitors of putative endogenous channels (Fig. 1C) . The I/V relationships in the absence (Fig. 1, A and B) and presence of these inhibitors (Fig. 1C) were similar. These data suggest that endogenous oocyte channels do not confound our observations.
Co-expression of G551D-CFTR and ␣␤␥-ENaC-Several groups have reported (7, 9 -11) that when WT CFTR and ENaC were co-expressed in Xenopus oocytes, ENaC-mediated Na ϩ currents were inhibited in response to CFTR activation. Furthermore, the co-expression of ENaC enhances forskolin/ IBMX-stimulated CFTR Cl Ϫ currents (7, 9 -11) . Therefore, we assessed the interregulation of G551D-CFTR and mENaC. Whole cell currents measured at a holding potential of Ϫ100 mV in oocytes injected with G551D-CFTR (10 ng) or ␣␤␥-ENaC (0.33 ng/subunit) or both G551D-CFTR and ␣␤␥-ENaC are shown Fig. 2 . In oocytes expressing ␣␤␥-ENaC, the amiloride-
FIG. 2. Expression of G551D-CFTR and ENaC in
sensitive whole cell currents measured at a clamp potential of Ϫ100 mV were similar in the absence or presence of 10 M forskolin and 100 M IBMX. These data are consistent with previous reports (7, 15) . Oocytes co-injected with G551D-CFTR and ␣␤␥-ENaC had 5-fold increased forskolin/IBMX-stimulated, amiloride-insensitive current compared with oocytes injected with G551D-CFTR alone ( Fig. 2A, I Cl ϭ Ϫ0.1 Ϯ 0.0 A (G551D-CFTR) versus Ϫ0.5 Ϯ 0.1 A (G551D-CFTR/␣␤␥-ENaC), p ϭ 0.007). Thus, a co-expression of ENaC in oocytes resulted in enhanced forskolin/IBMX-stimulated G551D-CFTR Cl Ϫ current similar to its previously described enhancement of WT CFTR current (7, 9 -11, 21) .
Oocytes co-injected with both G551D-CFTR and ENaC expressed amiloride-sensitive whole cell currents (Ϫ2.8 Ϯ 0.6 A, n ϭ 25) in the absence of forskolin/IBMX that were significantly lower than the amiloride-sensitive whole cell currents recorded in the absence of forskolin/IBMX in oocytes injected with ENaC alone (Ϫ5.3 Ϯ 1.0 A, n ϭ 22). However, similar levels of amiloride-sensitive whole cell currents were observed in oocytes co-injected with G551D-CFTR and ENaC prior to and after G551D-CFTR activation with forskolin/IBMX (Ϫ2.8 Ϯ 0.6 A versus Ϫ2.5 Ϯ 0.6 A, n ϭ 25, p ϭ n.s.) (Fig. 2B) , which is similar to ⌬F508-CFTR behavior and differs from WT CFTR behavior in this system (10, 11) .
G551D-CFTR/ENaC Interregulation with IBMX/Forskolin Does Not Require Sodium Transport-When Na
ϩ in the ND96 bath buffer was replaced by the impermeant cation NMDG ϩ , oocytes co-injected with G551D-CFTR and ␣␤␥-ENaC had a 6-fold increased forskolin/IBMX-stimulated whole cell current compared with oocytes injected with G551D-CFTR alone (I Cl ϭ Ϫ5.1 Ϯ 1.4-fold stimulation (ND96), n ϭ 25, versus Ϫ6.3 Ϯ 1.7-fold stimulation (NMDG-CL96), n ϭ 18, p ϭ n.s.) (Fig. 3) . These data suggest that ENaC enhancement of forskolin/ IBMX-mediated activation of G551D-CFTR is not dependent on extracellular Na ϩ , Na ϩ influx, or inward Na ϩ conductance.
Interregulation of G551D-CFTR and ␣␤␥-mENaC after IBMX/Forskolin/Genistein Stimulation-G551D-CFTR exhibits a poor Cl
Ϫ conductance in response to cAMP. As this might reflect the presence of alterations in other functional properties of this mutant, we examined whether genistein, which activates G551D-CFTR Cl Ϫ conductance, would restore functional interactions between G551D-CFTR and ENaC. As shown in Fig. 4A , the amiloride-insensitive component of the forskolin/ IBMX/genistein-stimulated whole cell current in oocytes coexpressing G551D-CFTR and ␣␤␥-ENaC was 4-fold greater than the forskolin/IBMX/genistein-stimulated current meas- FIG. 4 . Genistein restores regulation interactions between G551D-CFTR and ␣␤␥-ENaC. G551D-CFTR and ␣␤␥-ENaC were expressed separately or together in oocytes, and TEV was performed as described under "Experimental Procedures." A, changes in whole cell currents (Ϫ100-mV holding potential) after stimulation with 10 M forskolin, 100 M IBMX, and 50 M genistein that were not inhibited by 10 M amiloride (light gray bars) are illustrated. B, amiloride-sensitive whole cell currents (Ϫ100-mV holding potential) were determined in oocytes expressing ENaC or co-expressing ENaC and G551D-CFTR prior to (open bars) and following (dark gray bars) stimulation with 10 M forskolin, 100 M IBMX, and 50 M genistein. Data obtained from the same G551D-CFTR/ENaC-co-injected oocytes are presented in panels A and B. Means Ϯ S.E. are illustrated.
FIG. 3. G551D-CFTR/ENaC regulatory interactions restored by genistein do not require Na
؉ transport. Whole cell currents (Ϫ100-mV holding potential) were determined in oocytes expressing G551D-CFTR alone (open bars) or co-expressing G551D-CFTR and ␣␤␥-ENaC (closed bars). ND96, changes in whole cell currents that were not inhibited by 10 M amiloride (presumed to be G551D-CFTR-mediated) were determined following stimulation with 10 M forskolin and 100 M IBMX in standard ND96 (NaCl) buffer. NMDG-Cl96, changes in whole cell currents were determined following stimulation with 10 M forskolin and 100 M IBMX in oocytes bathed in a Na ϩ -free solution (Na ϩ was replaced with NMDG). Data (means Ϯ S.E.) are expressed relative to the mean change in whole cell current of oocytes injected with G551D-CFTR alone. ured in oocytes expressing G551D-CFTR alone (Ϫ0.
Consistent with our previous results (11), whole cell amiloride-sensitive currents modestly but significantly increased in response to 100 M IBMX, 10 M forskolin, and 50 M genistein (Ϫ5.9 Ϯ 1.3 A (Ϫforskolin/IBMX/genistein) versus Ϫ6.8 Ϯ 1.3 A (ϩforskolin/IBMX/genistein), n ϭ 21, p ϭ 0.05) in oocytes injected with ENaC alone (Fig. 4B) . Amiloride-sensitive whole cell currents recorded before and after stimulation by forskolin/ IBMX/genistein in oocytes expressing ENaC and G551D-CFTR were significantly lower than the amiloride-sensitive currents obtained both before and after stimulation by forskolin/IBMX/ genistein in oocytes expressing ENaC alone (Fig. 4B) . Although amiloride-sensitive whole cell currents significantly increased in oocytes expressing ENaC alone following stimulation by forskolin/IBMX/genistein (Fig. 4B) , amiloride-sensitive currents recorded in oocytes co-expressing ENaC and G551D-CFTR remained stable following stimulation with forskolin/ IBMX/genistein (Ϫ2.1 Ϯ 0.7 A (Ϫforskolin/IBMX/genistein) versus Ϫ2.0 Ϯ 0.3 (ϩforskolin/IBMX/genistein), n ϭ 20, p ϭ n.s.). These data suggest that the activation of G551D-CFTR by forskolin/IBMX in the presence of genistein partially restored the inhibition of ENaC activity by activated G551D-CFTR and are similar to our observations for ⌬F508-CFTR (11).
We again assessed whether the enhanced forskolin/IBMX/ genistein-stimulated amiloride-insensitive whole cell currents recorded in oocytes co-injected with G551D-CFTR and ENaC compared with oocytes injected with G551D-CFTR alone depended on ENaC-mediated sodium transport. Oocytes co-injected with G551D-CFTR and ␣␤␥-ENaC had a 3.75-fold increased forskolin/IBMX/genistein-stimulated G551D-CFTR Cl Ϫ current compared with oocytes injected with G551D-CFTR alone both in ND96 (NaCl) buffer and in NMDG-Cl buffer (Fig.  5) . These data suggest that ENaC enhancement of forskolin/ IBMX/genistein-mediated activation of G551D-CFTR is not dependent on extracellular Na ϩ , Na ϩ influx, or inward Na ϩ conductance. Fig. 6 , we have replotted the whole oocyte forskolin/ IBMX-stimulated (Fig. 3 , NMDG-Cl Ϫ ) or forskolin/IBMX/genistein-stimulated (Fig. 5 , NMDG-Cl Ϫ ) currents and expressed these relative to that of oocytes injected with G551D-CFTR alone and stimulated with IBMX/forskolin. In co-injected oocytes (ϩENaC), amiloride-insensitive forskolin/IBMX-stimulated currents increased 5.1-fold in the presence of ENaC and increased 14.6-fold in the presence of ENaC and genistein, whereas the amiloride-insensitive current increased only 3.9-fold in the presence of genistein alone. These data demonstrate synergistic activation of G551D-CFTR function by genistein and ENaC in the presence of forskolin/IBMX and suggest that genistein and ENaC enhance G551D-CFTR function in oocytes by different and complementary mechanisms.
Synergistic Activation of G551D-CFTR by Genistein and ENaC-In
Influence of ␣␤␥-mENaC on G551D-CFTR Single Channel Activity in Oocytes-We next sought to assess the mechanism by which ␣␤␥-mENaC increased G551D-CFTR-mediated current in co-injected oocytes. Oocytes were injected with G551D-CFTR alone or co-injected with ENaC, and G551D-CFTR was stimulated with forskolin/IBMX/genistein prior to single channel recordings of chloride transport (Fig. 7) . At a pipette potential of Ϫ80 mV in the cell-attached mode, single channel currents in G551D-CFTR-injected oocytes (1.08 Ϯ 0.13 pA, n ϭ 6) FIG. 6 . Synergistic activation of G551D-CFTR by genistein and ENaC. Whole oocyte IBMX/forskolin-stimulated (Fig. 3 , NMDG-Cl Ϫ ) or IBMX/forskolin/genistein-stimulated (Fig. 5 , NMDG-Cl Ϫ ) currents are replotted and expressed relative to that of oocytes injected with G551D-CFTR alone and stimulated with IBMX/forskolin. Means Ϯ S.E. are illustrated.
FIG. 5. G551D-CFTR/ENaC regulatory interactions restored by genistein do not require Na
؉ transport. Whole cell currents (Ϫ100-mV holding potential) were determined in oocytes expressing G551D-CFTR alone (open bars) or co-expressing G551D-CFTR and ␣␤␥-ENaC (closed bars). ND96, changes in whole cell currents that were not inhibited by 10 M amiloride (presumed to be G551D-CFTR-mediated) were determined following stimulation with 10 M forskolin, 100 M IBMX, and 50 M genistein in standard ND96 (NaCl) buffer. NMDG-Cl96, changes in whole cell currents were determined following stimulation with 10 M forskolin, 100 M IBMX, and 50 M genistein in oocytes bathed in a Na ϩ -free solution (Na ϩ was replaced with NMDG). Data (means Ϯ S.E.) are expressed relative to the mean change in whole cell current of oocytes injected with G551D-CFTR alone.
were similar in magnitude to the currents recorded in oocytes co-expressing G551D-CFTR and ENaC (0.92 Ϯ 0.14 pA, n ϭ 6, p ϭ n.s.). The P o for G551D-CFTR in oocytes co-injected with ENaC (0.24 Ϯ 0.6, mean Ϯ S.E., n ϭ 6) was not significantly different from that determined in oocytes injected with G551D-CFTR alone (0.29 Ϯ 0.2, n ϭ 6, p ϭ n.s.). We did not observe a difference in number of G551D-CFTR channels/patch from oocytes injected with G551D-CFTR alone (n ϭ 2, 3, 1, 2, 1, and 4 for n ϭ 6 patches) or co-injected with G551D-CFTR and ENaC (n ϭ 3, 1, 1, 4, 2, and 2 for n ϭ 6 patches). Given the difficulties in estimating small changes in channel density from single channel analyses and the lack of a difference in G551D-CFTR open probability following stimulation with forskolin/IBMX/ genistein in oocytes expressing G551D-CFTR alone or co-expressing G551D-CFTR and ENaC, our results are consistent with the increase in forskolin/IBMX/genistein-stimulated G551D-CFTR currents in the presence of ENaC, reflecting an increase in the number of G551D-CFTR channels at the plasma membrane. As genistein increases the P o for G551D-CFTR (22) , these data are consistent with genistein and ENaC enhancing G551D-CFTR function in oocytes by different and complementary mechanisms.
DISCUSSION
One hypothesis of the pathophysiology of the CF airway is that the absence of CFTR leads to increased ENaC activity in the airway epithelia, which results in increase solute and liquid absorption and decreased airway surface volume (23) . This up-regulation of Na ϩ absorption in CF airways has been attributed to defective or absent regulatory interactions between ENaC and mutants of CFTR. Previous studies have suggested that regulatory interactions between CFTR and ENaC in airway epithelia are replicated in Xenopus oocytes where functional expression of WT CFTR is associated with an inhibition of functional ENaC expression, making this system useful for studying these functional interactions.
The forskolin/IBMX-regulated inhibition of ENaC by CFTR does not require expression of the full-length CFTR protein.
The first nucleotide binding fold (nucleotide binding domain (NBD-1)) of CFTR in which G551D mutation is located seems important for this interaction. Forskolin/IBMX-dependent inhibition of ENaC can be observed when ENaC is co-expressed either with WT CFTR truncation mutants containing an intact first NBD-1 (24) or with a WT CFTR peptide fragment containing NBD-1 and the regulatory (R) domain (14) . A similar NBD-1/R peptide fragment containing the G551D mutation did not demonstrate forskolin/IBMX-regulated inhibition of ENaC (14) .
G551D-CFTR when co-expressed with ␣␤␥-ENaC and activated by IBMX/forskolin was unable to inhibit ENaC in our experiments. Similar results were obtained with ⌬F508-CFTR where the mutation is also located in NBD-1 (11) . These data suggest that form and/or function of NBD-1 are important in the inhibition of ENaC by CFTR and that genistein may improve ENaC regulation by mutant CFTR by influencing NBD-1. The importance of NBD-1 in this interaction is further suggested by our previous data regarding the interaction of ⌬F508-CFTR and ␣␤␥-mENaC. In these experiments, no ENaC-dependent increase in ⌬F508-CFTRmediated Cl Ϫ current or ⌬F508-CFTR-mediated regulation of ENaC was observed until ⌬F508-CFTR was further "repaired" with genistein (11) .
Genistein activates CFTR (WT, ⌬F508, and G551D) (16, 22) by increasing channel open time and decreasing channel closing, thereby increasing channel P o . Whereas the molecular details of this action remain elusive, some have suggested that genistein interacts directly with CFTR via the second nucleotide binding fold, NBD-2 (26). This is consistent with genistein being able to activate both ⌬F508-and G551D-CFTR as these two mutants have intact NBD-2s and further suggests that in some way an interaction of NBD-2 influences NBD-1 form and/or function.
The increase in CFTR-mediated whole cell Cl Ϫ conductance when WT CFTR is co-expressed with ␣␤␥-mENaC results from an increase in both CFTR open probability (10) and in N, the number of CFTR Cl Ϫ channels expressed at the plasma membrane (4, 8, 10) . In oocyte co-injected with G551D-CFTR and ␣␤␥-mENaC, the enhancement of G551D-CFTR Cl Ϫ current most probably correlates with an increase in the N or the number of Cl Ϫ channels present at the oocyte surface as the measured open probability of forskolin/IBMX/genistein-stimulated G551D-CFTR was the same in the presence or absence of ENaC.
We also observed that amiloride-inhibited whole oocyte currents decreased with co-expression of G551D-CFTR (in these studies) or with WT CFTR in our previous studies (11) . In contrast, we observed that ENaC functional expression was essentially unaltered by co-injection of ⌬F508-CFTR (11). One potential explanation for these observations is that co-expression of ENaC increases G551D-CFTR N, whereas co-expression of G551D-CFTR could decrease either ENaC N or open probability. Previous studies in a number of systems have suggested that co-expression of WT CFTR decreases ENaC open probability (21, 27) ; however, such an effect on open probability was not noted for G551D-CFTR in lipid bilayers (8) . Our data do not directly address this issue, but if G551D-CFTR does not decrease ENaC open probability in oocytes (similar to its behavior in lipid bilayers), we can speculate that G551D-CFTR inhibits ENaC functional expression via an N effect. This effect might result from altered trafficking of ENaC to the oocyte membrane, changing its rate of retrieval from the plasma membrane or both.
These considerations suggest that there may be multiple ways that CFTR and ENaC can interact. One interaction may be through competition for the folding/trafficking machinery. The co-expression of an appropriately folded and trafficked CFTR (G551D-CFTR as shown in Figs. 2 and 4 or WT) (11) would decrease the accessibility of this machinery for the folding and trafficking of ENaC, thereby decreasing ENaC functional expression and increasing CFTR functional expression. Conversely, co-expression of an inefficiently folded and trafficked CFTR (like ⌬F508-CFTR) would not inhibit ENaC access to folding and trafficking machinery and result in unaltered functional ENaC expression in the presence of ⌬F508-CFTR as we observed previously (11) .
Another potential site of interaction/competition between CFTR and ENaC is at the plasma membrane where cAMPactivated WT CFTR but not G551D-CFTR and ⌬F508-CFTR inhibited ENaC function. One possibility is that both G551D-CFTR and ⌬F508-CFTR undergo more rapid removal from the plasma membrane when compared with WT CFTR as has been suggested for ⌬F508-CFTR (25) . Another possibility is that G551D-CFTR and ⌬F508-CFTR, perhaps because of their aberrant NBD-1s, are not able to interact or interact differently with either ENaC or proteins important in transducing cAMPactivated CFTR signal to inhibit ENaC function.
These considerations suggest a potential added level of complexity in considering pharmacologic repair of mutant CFTR function. Current investigational strategies, such as combinations of agents to improve CFTR trafficking such as 4-phenylbutyrate for ⌬F508-CFTR, given together with genistein to activate the mutant CFTR and restore its interaction with ENaC may require further refinement. Additional agents that modulate ENaC functional expression when added to current combinations may further bolster such therapeutic strategies for pharmacologic repair therapy for mutant CFTR.
